Oramed reports successful insulin suppository study

The oral drug delivery company has completed a proof of concept study in South Africa on its insulin suppositories.

Oramed Pharmaceuticals Inc. (Bulletin Board:ORMP); DAX:OJU), a developer of drug delivery systems, has concluded a proof of concept study in South Africa of insulin suppositories, ORMD-0802, using its proprietary technology.

In the study, eight healthy volunteers came for two visits, with two different formulations. The insulin suppositories showed rapid insulin absorption and reactive glucose lowering effect and were well tolerated, while no adverse events were encountered.

Oramed proposes insulin suppositories as a treatment alternative for injectable insulin. Such an alternative may be especially useful for individuals with immunological-based reactions to repeated injections and who require a temporary recess from daily injections.

Suppositories are often used in pediatrics for the treatment of conditions such as nausea and vomiting, sedation, analgesia, control of seizures, or anti-pyresis. Suppositories also provide rapid absorption and have the advantage of being relatively painless.

Headquartered in Jerusalem, Oramed is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection based on research by top scientists at Jerusalem's Hadassah Medical Center.

Oramed's share closed at $0.37 on the OTC Bulletin Board.

Published by Globes [online], Israel business news - www.globes-online.com - on February 8, 2009

© Copyright of Globes Publisher Itonut (1983) Ltd. 2009

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018